Immuneering Corporation (IMRX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 8.12M USD | Liabilities, Current |
| Cash and equivalents | 41.32M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $8.12M | $41.32M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $4.97M | $47.32M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $10.07M | $128.65M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $9.55M | $227.56M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $7.49M | $26.36M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $5.11M | $35.87M | $0.00 | (m) | (m) | (m) |
| 2024-12-31 | (m) | $7.50M | $36.14M | $0.00 | (m) | (m) | (m) |
| 2024-09-30 | (m) | $6.92M | $45.21M | $5.45M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $6.78M | $59.73M | $0.00 | (m) | (m) | (m) |
| 2024-03-31 | (m) | $5.18M | $66.29M | $4.99M | (m) | (m) | (m) |
| 2023-12-31 | $85.67M | $7.85M | $59.41M | $26.26M | $0.00 | (m) | 10.92× |
| 2023-09-30 | $97.24M | $5.62M | $68.04M | $29.20M | $0.00 | (m) | 17.30× |
| 2023-06-30 | $108.99M | $5.48M | $104.02M | $4.97M | $0.00 | (m) | 19.89× |
| 2023-03-31 | $91.54M | $5.53M | $77.43M | $14.11M | $1.05K | (m) | 16.57× |
| 2022-12-31 | $105.54M | $8.05M | $72.64M | $32.89M | $12.42K | (m) | 13.10× |
| 2022-09-30 | $117.27M | $7.26M | $76.42M | $40.78M | $70.18K | (m) | 16.16× |
| 2022-06-30 | $128.28M | $3.80M | $87.94M | $40.16M | $178.43K | (m) | 33.75× |
| 2022-03-31 | $138.05M | $3.67M | $75.21M | $62.57M | $279.61K | (m) | 37.58× |
| 2021-12-31 | $149.45M | $5.63M | $74.89M | $74.31M | $246.04K | (m) | 26.53× |
| 2021-09-30 | $149.95M | $5.27M | $106.93M | $42.55M | $471.38K | (m) | 28.47× |
| 2021-06-30 | (m) | $4.83M | $50.25M | (m) | $495.11K | (m) | (m) |
| 2020-12-31 | (m) | $2.26M | $37.09M | (m) | $500.11K | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |